type here...
type here...
START FREE TRIAL

Healthcare

Technology & AIHealthcareM&AConsumer & RetailEnergyMiscellaneous

This Medical Device Stock Just Got CRUSHED On One Hidden Number; Did Wall Street Misread It?

Healthcare Ishan Majumdar -
Boston Scientific (NYSE:BSX) spent the weekend putting forward what looked, at first glance, like a clinically solid case for Watchman FLX. The device met...

A First-In-Class Biotech Is Still Trading Below Its Strategic Value Today

Healthcare Ishan Majumdar -
A mid-cap biotech with the first approved therapy in a large, long-underfunded liver disease category is not supposed to look this inexpensive after delivering...
spot_imgspot_img

Is Align A Classic Activist Win, Or A HARDER Consumer Story?

Healthcare Ishan Majumdar -
Align Technology (NASDAQ:ALGN) has become a useful test case for a very modern market question. What happens when Wall...

Qiagen Just Dropped Two Magic Words—And Wall Street Heard “Buyout”

Healthcare Ishan Majumdar -
Qiagen (NYSE:QGEN) just did the thing companies do right before Wall Street starts whispering louder. On March 2, CEO...

Is Merck’s HIV Win Really About Keytruda?

Healthcare Ishan Majumdar -
When Merck & Co. (NYSE:MRK) reported Phase 3 data showing its two-drug HIV regimen of doravirine and islatravir matched...

Did Novo Nordisk’s Trial Miss Just Hand Lilly The Edge?

Healthcare Ishan Majumdar -
It has been a bruising few weeks for Novo Nordisk (NYSE:NVO). First came the clinical disappointment: CagriSema, the company’s...

Did Moderna’s Flu Rejection Signal A Deeper FDA SHIFT?

Healthcare Ishan Majumdar -
Moderna’s seasonal flu vaccine application was refused review by the FDA, triggering an immediate stock decline. The agency issued...

Hims & Hers Just Went Big on Cancer—But the DOJ Is Watching

Healthcare Ishan Majumdar -
Hims & Hers used the Super Bowl stage to push its latest offering: a $689 early cancer detection test....
Load more

This Medical Device Stock Just Got CRUSHED On One Hidden Number; Did Wall Street Misread It?

Healthcare Ishan Majumdar -
Boston Scientific (NYSE:BSX) spent the weekend putting forward what looked, at first glance, like a clinically solid case for...

A First-In-Class Biotech Is Still Trading Below Its Strategic Value Today

Healthcare Ishan Majumdar -
A mid-cap biotech with the first approved therapy in a large, long-underfunded liver disease category is not supposed to...

Is Align A Classic Activist Win, Or A HARDER Consumer Story?

Healthcare Ishan Majumdar -
Align Technology (NASDAQ:ALGN) has become a useful test case for a very modern market question. What happens when Wall...

Qiagen Just Dropped Two Magic Words—And Wall Street Heard “Buyout”

Healthcare Ishan Majumdar -
Qiagen (NYSE:QGEN) just did the thing companies do right before Wall Street starts whispering louder. On March 2, CEO...

Is Merck’s HIV Win Really About Keytruda?

Healthcare Ishan Majumdar -
When Merck & Co. (NYSE:MRK) reported Phase 3 data showing its two-drug HIV regimen of doravirine and islatravir matched...

Did Novo Nordisk’s Trial Miss Just Hand Lilly The Edge?

Healthcare Ishan Majumdar -
It has been a bruising few weeks for Novo Nordisk (NYSE:NVO). First came the clinical disappointment: CagriSema, the company’s...

Did Moderna’s Flu Rejection Signal A Deeper FDA SHIFT?

Healthcare Ishan Majumdar -
Moderna’s seasonal flu vaccine application was refused review by the FDA, triggering an immediate stock decline. The agency issued...

Hims & Hers Just Went Big on Cancer—But the DOJ Is Watching

Healthcare Ishan Majumdar -
Hims & Hers used the Super Bowl stage to push its latest offering: a $689 early cancer detection test....

Pfizer Takes On Eli Lilly & Novo: Who Gets OUTPLAYED in the Obesity Arms Race?

Healthcare Ishan Majumdar -
Pfizer just released mid-stage data from its Metsera-acquired obesity drug showing 12.3% weight loss at 28 weeks with monthly...

UnitedHealth CRASHES After Shocking Medicare Ruling — The Fallout Explained!

Healthcare Ishan Majumdar -
When a 0.09% number sends $96 billion out the window, you know something serious just happened. On January 27,...

Boston Scientific Penumbra Acquisition: The $15 Billion Gamble That Could Dominate Neurovascular Markets

Healthcare Ishan Majumdar -
If you're wondering what Boston Scientific (NYSE:BSX) has been up to lately, buckle up. On January 15, the medtech...

AbbVie Trump Investment Deal: How Medicaid Cuts Bought Regulatory Peace!

Healthcare Ishan Majumdar -
AbbVie (NYSE:ABBV) just made a bold move—and the stakes are massive. The company agreed to invest $100 billion into...
Load more

Baptista Research is a financial research house focused on the U.S. markets. We cover the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms.

Company

Headlines

This AI Infra Stock Could Anchor 6G And Edge Computing; PE Knows It’s MISPRICED!

0
There’s a reason SBA Communications (NASDAQ: SBAC) has suddenly...

Unilever’s $42 Billion Selloff Is Hiding a Much BIGGER Bet!

0
Unilever (NYSE: UL) did not just announce a deal—it...

Nike’s China Slump Is Starting to Look Like Something More!

0
Nike (NYSE:NKE) has spent years selling the idea that...

This “Broken” Biotech Just Forced Wall Street To Blink

0
Apellis Pharmaceuticals (NASDAQ:APLS) did not suddenly discover a miracle...

Newsletter

Get important news delivered directly to your inbox and stay connected!

Copyright © 2026 Baptista Research. All rights reserved.